Drug intelligence / Profile preview

PA3670

Development stage: Phase 1
Lead developer: Apeloa
Modality: Small Molecules
Administration: Oral

Overview

PA3670 is an orally bioavailable small molecule drug under development by Zhejiang Palo Alto Pharmaceuticals for the treatment of chronic hepatitis B virus (HBV) infection. The drug has reached Phase 1 clinical trials, where its safety, tolerability, pharmacokinetics, and the effect of food on its pharmacokinetics are being evaluated in healthy subjects. Its primary therapeutic area is infectious diseases, specifically chronic hepatitis B. The precise mechanism of action and molecular target have not been publicly disclosed[1][2][6].

Beyond the preview

Go deeper on PA3670.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PA3670.

Explore the full profile